News & Updates
Filter by Specialty:
Why do psoriasis patients report better QoL amid COVID-19?
Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.
Why do psoriasis patients report better QoL amid COVID-19?
04 Oct 2022Brensocatib has no impact on COVID-19 clinical outcomes
Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.
Brensocatib has no impact on COVID-19 clinical outcomes
02 Oct 2022Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
30 Sep 2022FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
28 Sep 2022Are healthcare workers more stressed out during the COVID-19 pandemic?
Burnout continues to be a burden among healthcare workers (HCWs) during the COVID-19 pandemic despite the lack of quality research with pre-COVID-19 data, according to a Singapore study.
Are healthcare workers more stressed out during the COVID-19 pandemic?
27 Sep 2022Sotrovimab of no help in attenuating COVID-19 severity in face of Omicron BA.2 subvariant
Treatment with sotrovimab does not appear to confer protection against severe forms of COVID-19 in a setting dominated by the Omicron BA.2 subvariant, a study has found.